A Polymorphism in the VKORC1 Regulator Calumenin Predicts Higher Warfarin Dose Requirements in African Americans

A genome-wide association study of acenocoumarol maintenance dosage

(2009) Martina Teichert et al.   HUMAN MOLECULAR GENETICS

A Genome-Wide Association Study Confirms VKORC1, CYP2C9, and CYP4F2 as Principal Genetic Determinants of Warfarin Dose

(2009) Fumihiko Takeuchi et al.   PLoS Genetics

CYP4F2 genetic variant alters required warfarin dose

(2008) M. D. Caldwell et al.   BLOOD

The largest prospective warfarin-treated cohort supports genetic forecasting

(2008) M. Wadelius et al.   BLOOD

A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose

(2008) G. M. Cooper et al.   BLOOD

Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of Warfarin

(2008) BF Gage et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

WGAViewer: Software for genomic annotation of whole genome association studies

(2008) D. Ge et al.   GENOME RESEARCH

Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients

(2008) P. A. LENZINI et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Dosing anticoagulant therapy with coumarin drugs: is genotyping clinically useful? Yes

(2008) S. M. THACKER et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

VKORC1polymorphisms, haplotypes and haplotype groups on warfarin dose among African–Americans and European–Americans

(2008) Nita A Limdi et al.   PHARMACOGENOMICS

Influence ofCYP2C9andVKORC1on warfarin dose, anticoagulation attainment and maintenance among European–Americans and African–Americans

(2008) Nita A Limdi et al.   PHARMACOGENOMICS

Enhanced functional recombinant factor VII production by HEK 293 cells stably transfected with VKORC1 where the gamma-carboxylase inhibitor calumenin is stably suppressed by shRNA transfection

(2008) Nadeem Wajih et al.   THROMBOSIS RESEARCH